The federal government is preparing to revise dietary recommendations regarding saturated fats, with the health secretary indicating that new guidelines will emphasize the need to consume these fats. This shift follows a review of research suggesting potential benefits of reducing saturated fat intake.

Sanofi's shares have declined following a U.S. regulatory decision to delay the approval of tolebrutinib, a drug intended for treating multiple sclerosis. This setback comes as a late-stage trial for a different form of the disease failed to meet its primary endpoint.

Companies such as Cigna and CVS are making commitments to provide simpler drug pricing structures, aiming to enhance transparency for consumers. However, the underlying systems that dictate drug pricing remain intricate and challenging to navigate, indicating that the promise of simplicity may not fully materialize in practice.

Rival healthcare proposals have failed, prompting drugmakers to move away from using middlemen in their distribution processes. Additionally, Lilly has reported on its next-generation weight-loss drug, indicating advancements in pharmaceutical offerings.

Roche announced that its breast-cancer drug, Giredestrant, has demonstrated a 30% reduction in the risk of disease recurrence or death compared to standard endocrine therapy. This finding suggests a significant advancement in treatment options for breast cancer patients.

Eli Lilly has announced plans to build a $6 billion manufacturing plant in Alabama, marking the third of four new facilities the pharmaceutical company intends to establish in the United States. This investment is part of Eli Lilly's broader strategy to enhance its production capabilities and meet increasing demand for its products.